

Teclistamab

Cat. No.:	HY-P99392
CAS No.:	2119595-80-9
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) ^[1] .								
In Vitro	Teclistamab (0.01-1000 nM, 48 h) induces T cell-mediated cytotoxicity with the EC ₅₀ values of 0.15 nM in H929 cells, 0.06 nM in MM.1R cell lines, and 0.45 nM in RPMI 8226 cell lines, respectively ^[1] . Teclistamab (0.01-1000 nM, 48 h) can bind CD138 ⁺ human BM monocytes in a dose-dependent manner and induces cytotoxicity of human BM monocytes ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Teclistamab (i.v., 0.1-1 µg, once every 2 days) has anti-tumor activity at high doses in female NSG (NOD/SCID/γc ^{-/-}) mice with H929 cells model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Female NSG mice infected with H929 cell lines^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.1 µg (0.005 mg/kg), 0.5 µg (0.025 mg/kg), or 1 µg (0.05 mg/kg)</td> </tr> <tr> <td>Administration:</td> <td>i.v., on days 0, 3, 5, 7, and 10</td> </tr> <tr> <td>Result:</td> <td>Completely inhibited tumor growth at doses of 0.5 and 1 µg, while no inhibition of tumor growth was observed at a dose of 0.1 µg.</td> </tr> </table>	Animal Model:	Female NSG mice infected with H929 cell lines ^[1]	Dosage:	0.1 µg (0.005 mg/kg), 0.5 µg (0.025 mg/kg), or 1 µg (0.05 mg/kg)	Administration:	i.v., on days 0, 3, 5, 7, and 10	Result:	Completely inhibited tumor growth at doses of 0.5 and 1 µg, while no inhibition of tumor growth was observed at a dose of 0.1 µg.
Animal Model:	Female NSG mice infected with H929 cell lines ^[1]								
Dosage:	0.1 µg (0.005 mg/kg), 0.5 µg (0.025 mg/kg), or 1 µg (0.05 mg/kg)								
Administration:	i.v., on days 0, 3, 5, 7, and 10								
Result:	Completely inhibited tumor growth at doses of 0.5 and 1 µg, while no inhibition of tumor growth was observed at a dose of 0.1 µg.								

REFERENCES

[1]. Kodandaram Pillarisetti, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA